This trial was open to participants who had received a liver transplant or had cirrhosis due
to chronic HCV. All subjects were treated with daclatasvir+sofosbuvir+ribavirin and were
followed for 24 weeks post treatment. Under certain conditions, the treatment duration could
have been extended for cirrhotic participants. The study tested the...Read More
efficacy and safety of
this combination for treatment of HCV in cirrhotic and post transplant patients.Read Less
Ask a Question?
Ask your question and our customer service team will answer it as soon as they can. Questions that do not contain personal information may be posted to our help center to be of service to others
Please enter valid email address.
Please enter all required fields.
